BioSpace News Archive

Oncotelic Therapeutics, Inc, unveils a state-of-the-art GMP Manufacturing Plant, a significant stride in biopharmaceutical innovation, through its joint venture Sapu Biosciences LLC.

Waters Corporation announced that its Board of Directors has been named 2024 “Public Company Board of the Year” by the National Association of Corporate Directors New England Chapter.

Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of best-in-class IL-2 therapeutics, today announced plans to initiate the Phase 2 portion of its Phase 1/2 clinical trial of AU-007 in patients with unresectable locally advanced or metastatic solid tumor cancers of the skin and kidney.

Bone Biologics Corporation, a developer of orthobiologic products for spine fusion markets, announced a planned reverse stock split of its shares of common stock at a ratio of 1-for-8.

Jeff Wolf, CEO of NightHawk, commented, “We are generating strong interest in our CDMO services, given our state-of-the-art facility and the industry-wide lack of available capacity for large molecule manufacturing.

Inspira Technologies OXY BHN Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the “Company” or “Inspira”) today announced that its CEO and the Company’s President will attend the upcoming 42nd Annual J.P. Morgan Healthcare Conference taking place January 8-11, 2024 in San Francisco, California.

AnHeart Therapeutics (“AnHeart”) and Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, today announced the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has granted Priority Review Designation for the New Drug Application (NDA) of taletrectinib.

Trinity Life Sciences, a leader in global life sciences commercialization solutions, introduces a Cell & Gene Therapy Center of Excellence that supports life sciences companies in successfully commercializing a C> asset.

GE HealthCare (Nasdaq: GEHC) is announcing today that President and Chief Executive Officer, Peter Arduini, and Vice President and Chief Financial Officer, Jay Saccaro, will attend the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9th in San Francisco.

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announces an antibody evaluation, option and license agreement with Ona Therapeutics (“Ona”), a Spanish biotech company specialized in unravelling novel biology to design biopharmaceuticals attacking advanced cancer.